Published in Dig Dis Sci on March 03, 2009
Predictors of severe outcomes associated with Clostridium difficile infection in patients with inflammatory bowel disease. Aliment Pharmacol Ther (2012) 1.67
Disproportionate rise in Clostridium difficile-associated hospitalizations among US youth with inflammatory bowel disease, 1997-2011. J Pediatr Gastroenterol Nutr (2015) 1.46
Defining quality indicators for best-practice management of inflammatory bowel disease in Canada. Can J Gastroenterol Hepatol (2014) 1.19
Clostridium difficile Infection and Inflammatory Bowel Disease: A Review. Gastroenterol Res Pract (2011) 1.11
Clostridium difficile and inflammatory bowel disease: role in pathogenesis and implications in treatment. World J Gastroenterol (2013) 1.03
Quality of care delivered to hospitalized inflammatory bowel disease patients. World J Gastroenterol (2013) 1.02
Clostridium difficile infection and inflammatory bowel disease: understanding the evolving relationship. World J Gastroenterol (2010) 0.97
Higher plasma vitamin D is associated with reduced risk of Clostridium difficile infection in patients with inflammatory bowel diseases. Aliment Pharmacol Ther (2014) 0.95
Genetic risk factors for Clostridium difficile infection in ulcerative colitis. Aliment Pharmacol Ther (2013) 0.95
Environmental risk factors for inflammatory bowel disease. Gastroenterol Hepatol (N Y) (2013) 0.93
Fecal Bacteriotherapy: A Case Report in an Immunosuppressed Patient with Ulcerative Colitis and Recurrent Clostridium difficile Infection. Case Rep Infect Dis (2012) 0.85
Review of medical and surgical management of Clostridium difficile infection. Tech Coloproctol (2010) 0.85
WSES guidelines for management of Clostridium difficile infection in surgical patients. World J Emerg Surg (2015) 0.85
Cumulative incidence and risk factors for hospitalization and surgery in a population-based cohort of ulcerative colitis. Inflamm Bowel Dis (2013) 0.83
Antibiotics for Treatment of Clostridium difficile Infection in Hospitalized Patients with Inflammatory Bowel Disease. Antimicrob Agents Chemother (2014) 0.83
Ulcerative Colitis Patients With Clostridium difficile are at Increased Risk of Death, Colectomy, and Postoperative Complications: A Population-Based Inception Cohort Study. Am J Gastroenterol (2016) 0.80
Impact of Clostridium difficile infection on inflammatory bowel disease outcome: a review. World J Gastroenterol (2014) 0.79
Clostridium difficile infection in patients with inflammatory bowel disease. Ann Gastroenterol (2011) 0.78
Environmental risk factors for inflammatory bowel diseases: Evidence based literature review. World J Gastroenterol (2016) 0.76
The impact of Clostridum difficile on surgical rate among ulcerative colitis patients: A systemic review and meta-analysis. Saudi J Gastroenterol (2015) 0.75
Ulcerative colitis worsened after Clostridium difficile infection: efficacy of infliximab. World J Gastroenterol (2014) 0.75
Clostridium difficile Infection: A Rarity in Patients Receiving Chronic Antibiotic Treatment for Crohn's Disease. Inflamm Bowel Dis (2016) 0.75
Management of inflammatory bowel disease with Clostridium difficile infection. World J Gastroenterol (2017) 0.75
Clostridium difficile colitis. N Engl J Med (1994) 9.31
Secular trends in hospital-acquired Clostridium difficile disease in the United States, 1987-2001. J Infect Dis (2004) 3.42
Excess hospitalisation burden associated with Clostridium difficile in patients with inflammatory bowel disease. Gut (2007) 3.09
Clostridium difficile associated diarrhoea: a role in inflammatory bowel disease? Lancet (1980) 2.26
Therapeutic implications of Clostridium difficile toxin during relapse of chronic inflammatory bowel disease. Lancet (1980) 2.24
Impact of Clostridium difficile on inflammatory bowel disease. Clin Gastroenterol Hepatol (2007) 2.20
Incidence of Clostridium difficile infection in inflammatory bowel disease. Clin Gastroenterol Hepatol (2007) 1.78
Comparison of the TOX A/B test to a cell culture cytotoxicity assay for the detection of Clostridium difficile in stools. Diagn Microbiol Infect Dis (2000) 1.49
Association of Clostridium difficile toxin with symptomatic relapse of chronic inflammatory bowel disease. Gastroenterology (1981) 1.42
Enteric infection in relapse of inflammatory bowel disease: importance of microbiological examination of stool. Eur J Gastroenterol Hepatol (2004) 1.22
Clostridium difficile and inflammatory bowel disease. Gut (1983) 1.20
Occurrence of Clostridium difficile toxin during the course of inflammatory bowel disease. Gastroenterology (1981) 1.16
The diagnostic yield of stool pathogen studies during relapses of inflammatory bowel disease. J Clin Gastroenterol (2004) 1.09
Evaluation of three rapid assays for detection of Clostridium difficile toxin A and toxin B in stool specimens. Eur J Clin Microbiol Infect Dis (2007) 0.94
Microbic superinfection in relapse of inflammatory bowel disease. J Clin Gastroenterol (1992) 0.90
Role of infectious agents in exacerbations of ulcerative colitis in India. A study of Clostridium difficile. J Clin Gastroenterol (1993) 0.76
Toll-like receptor-4 is required for intestinal response to epithelial injury and limiting bacterial translocation in a murine model of acute colitis. Am J Physiol Gastrointest Liver Physiol (2005) 4.28
Toll-like receptor-4 promotes the development of colitis-associated colorectal tumors. Gastroenterology (2007) 3.99
Pro-inflammatory human Th17 cells selectively express P-glycoprotein and are refractory to glucocorticoids. J Exp Med (2014) 2.98
Human intestinal epithelial cells are broadly unresponsive to Toll-like receptor 2-dependent bacterial ligands: implications for host-microbial interactions in the gut. J Immunol (2003) 2.96
Cox-2 is regulated by Toll-like receptor-4 (TLR4) signaling: Role in proliferation and apoptosis in the intestine. Gastroenterology (2006) 2.78
6-MP metabolite profiles provide a biochemical explanation for 6-MP resistance in patients with inflammatory bowel disease. Gastroenterology (2002) 2.35
Thioguanine: a potential alternate thiopurine for IBD patients allergic to 6-mercaptopurine or azathioprine. Am J Gastroenterol (2003) 2.20
Chromoendoscopy-targeted biopsies are superior to standard colonoscopic surveillance for detecting dysplasia in inflammatory bowel disease patients: a prospective endoscopic trial. Am J Gastroenterol (2008) 2.16
Beta-defensin-2 expression is regulated by TLR signaling in intestinal epithelial cells. J Immunol (2004) 2.05
Antibiotic therapy in inflammatory bowel disease: a systematic review and meta-analysis. Am J Gastroenterol (2011) 2.04
6-thioguanine can cause serious liver injury in inflammatory bowel disease patients. Gastroenterology (2003) 1.95
Safety and efficacy of adalimumab (D2E7) in Crohn's disease patients with an attenuated response to infliximab. Am J Gastroenterol (2005) 1.93
Toll-like receptor signaling in small intestinal epithelium promotes B-cell recruitment and IgA production in lamina propria. Gastroenterology (2008) 1.89
Inflammatory bowel disease is associated with an increased incidence of cardiovascular events. Am J Gastroenterol (2011) 1.88
Developing an instrument to assess the endoscopic severity of ulcerative colitis: the Ulcerative Colitis Endoscopic Index of Severity (UCEIS). Gut (2011) 1.80
American Gastroenterological Association Institute technical review on corticosteroids, immunomodulators, and infliximab in inflammatory bowel disease. Gastroenterology (2006) 1.78
The myeloid differentiation factor 88 (MyD88) is required for CD4+ T cell effector function in a murine model of inflammatory bowel disease. J Immunol (2008) 1.75
Toll-like receptors (TLRs) and Nod-like receptors (NLRs) in inflammatory disorders. Semin Immunol (2009) 1.66
Outcome measurement in clinical trials for Ulcerative Colitis: towards standardisation. Trials (2007) 1.62
Placental transfer of anti-tumor necrosis factor agents in pregnant patients with inflammatory bowel disease. Clin Gastroenterol Hepatol (2012) 1.57
Innate immune signaling by Toll-like receptor-4 (TLR4) shapes the inflammatory microenvironment in colitis-associated tumors. Inflamm Bowel Dis (2009) 1.53
A genome-wide scan of Ashkenazi Jewish Crohn's disease suggests novel susceptibility loci. PLoS Genet (2012) 1.52
Defects in mucosal immunity leading to Crohn's disease. Immunol Rev (2005) 1.48
American Gastroenterological Association Institute medical position statement on corticosteroids, immunomodulators, and infliximab in inflammatory bowel disease. Gastroenterology (2006) 1.43
An evidence-based systematic review on medical therapies for inflammatory bowel disease. Am J Gastroenterol (2011) 1.42
The impact of Hispanic ethnicity and race on post-surgical complications in patients with inflammatory bowel disease. Dig Dis Sci (2013) 1.40
A novel Toll-like receptor 4 antagonist antibody ameliorates inflammation but impairs mucosal healing in murine colitis. Am J Physiol Gastrointest Liver Physiol (2009) 1.39
Exercise attenuates PCB-induced changes in the mouse gut microbiome. Environ Health Perspect (2013) 1.33
Anti-flagellin (CBir1) phenotypic and genetic Crohn's disease associations. Inflamm Bowel Dis (2007) 1.33
Constitutive activation of epithelial TLR4 augments inflammatory responses to mucosal injury and drives colitis-associated tumorigenesis. Inflamm Bowel Dis (2010) 1.28
Toll-like receptor 4 differentially regulates epidermal growth factor-related growth factors in response to intestinal mucosal injury. Lab Invest (2010) 1.23
NOD2 variants and antibody response to microbial antigens in Crohn's disease patients and their unaffected relatives. Gastroenterology (2006) 1.20
Certolizumab pegol in patients with moderate to severe Crohn's disease and secondary failure to infliximab. Clin Gastroenterol Hepatol (2010) 1.19
Glucocorticosteroid therapy in inflammatory bowel disease: systematic review and meta-analysis. Am J Gastroenterol (2011) 1.14
Pathogen recognition receptors, cancer and inflammation in the gut. Curr Opin Pharmacol (2009) 1.14
Reliability and initial validation of the ulcerative colitis endoscopic index of severity. Gastroenterology (2013) 1.14
Advances in the pathogenesis of inflammatory bowel disease. Curr Gastroenterol Rep (2006) 1.12
Evaluation of 22 genetic variants with Crohn's disease risk in the Ashkenazi Jewish population: a case-control study. BMC Med Genet (2011) 1.10
TLR4 activates the β-catenin pathway to cause intestinal neoplasia. PLoS One (2013) 1.10
A pilot study of adalimumab in infliximab-allergic patients. Inflamm Bowel Dis (2004) 1.07
The spectrum of gastrointestinal toxicity and effect on disease activity of selective cyclooxygenase-2 inhibitors in patients with inflammatory bowel disease. Inflamm Bowel Dis (2004) 1.05
Predictors of aggressive inflammatory bowel disease. Gastroenterol Hepatol (N Y) (2011) 1.02
Biomarkers in inflammatory bowel disease. Curr Opin Gastroenterol (2004) 1.01
Innate immunity in the small intestine. Curr Opin Gastroenterol (2012) 1.01
Innate immunity in the small intestine. Curr Opin Gastroenterol (2011) 1.01
Phenotypic manifestations of inflammatory bowel disease differ between Hispanics and non-Hispanic whites: results of a large cohort study. Am J Gastroenterol (2012) 1.00
Ulcerative colitis therapy: importance of delivery mechanisms. Rev Gastroenterol Disord (2005) 0.98
Regulation of Toll-like receptor 4-associated MD-2 in intestinal epithelial cells: a comprehensive analysis. Innate Immun (2009) 0.97
Antibodies to I2 predict clinical response to fecal diversion in Crohn's disease. Inflamm Bowel Dis (2006) 0.94
Cancer in inflammatory bowel disease: lessons from animal models. Curr Opin Gastroenterol (2012) 0.93
The role of prostaglandin E2 (PGE 2) in toll-like receptor 4 (TLR4)-mediated colitis-associated neoplasia. BMC Gastroenterol (2010) 0.93
Hepatotoxicity of 6-mercaptopurine (6-MP) and Azathioprine (AZA) in adult IBD patients. Am J Gastroenterol (2007) 0.88
Aberrant expression of the polarity complex atypical PKC and non-muscle myosin IIA in active and inactive inflammatory bowel disease. Virchows Arch (2011) 0.87
Early hepatic nodular hyperplasia and submicroscopic fibrosis associated with 6-thioguanine therapy in inflammatory bowel disease. Am J Surg Pathol (2004) 0.87
Infusion reactions and their management. Gastroenterol Clin North Am (2006) 0.86
How are Azathioprine and 6-mercaptopurine dosed by gastroenterologists? Results of a survey of clinical practice. Inflamm Bowel Dis (2008) 0.86
Role of vascular endothelial growth factor and angiopoietin systems in serum of Crohn's disease patients. Inflamm Bowel Dis (2008) 0.85
Increased toll-like receptor 4 in cerebral endothelial cells contributes to the astrocyte swelling and brain edema in acute hepatic encephalopathy. J Neurochem (2013) 0.85
Microflora in colorectal cancer: a friend to fear. Nat Med (2010) 0.84
The innate immune system and inflammatory bowel disease. Scand J Gastroenterol (2015) 0.82
Combination of innate and adaptive immune alterations increased the likelihood of fibrostenosis in Crohn's disease. Inflamm Bowel Dis (2010) 0.82
Practical techniques for detection of Toll-like receptor-4 in the human intestine. Methods Mol Biol (2009) 0.82
In silico and Ex vivo approaches identify a role for toll-like receptor 4 in colorectal cancer. J Exp Clin Cancer Res (2014) 0.82
Lipopolysaccharide potentiates polychlorinated biphenyl-induced disruption of the blood-brain barrier via TLR4/IRF-3 signaling. Toxicology (2012) 0.81
Antibodies to tumor necrosis factor-alpha in the treatment of Crohn's disease. Curr Opin Drug Discov Devel (2005) 0.81
Higher Adalimumab Levels Are Associated with Histologic and Endoscopic Remission in Patients with Crohn's Disease and Ulcerative Colitis. Inflamm Bowel Dis (2016) 0.80
Use of capsule endoscopy for established Crohn's disease. Gastrointest Endosc Clin N Am (2006) 0.79
Design issues and outcomes in IBD clinical trials. Inflamm Bowel Dis (2005) 0.79
Re: underrepresentation of underrepresented minorities in academic medicine. Gastroenterology (2010) 0.79
Host-microbe interactions in the small bowel. Curr Opin Gastroenterol (2015) 0.79
What are toll-like receptors and what role may they have in IBD? Inflamm Bowel Dis (2008) 0.79
Isolation and characterization of the ecdysone receptor and its heterodimeric partner ultraspiracle through development in Sciara coprophila. Chromosoma (2013) 0.79
FcRL3 gene promoter variant is associated with peripheral arthritis in Crohn's disease. Inflamm Bowel Dis (2009) 0.78
What is the role and significance of serum and stool biomarkers in the diagnosis of IBD? Inflamm Bowel Dis (2008) 0.78
Genetics in diagnosing and managing inflammatory bowel disease. Gastroenterol Clin North Am (2012) 0.77
Harnessing the power of bacteria to protect the gut. N Engl J Med (2008) 0.77
Update on idiopathic colitides. Curr Opin Gastroenterol (2013) 0.77
New insights into the pathogenesis of inflammatory bowel disease. Curr Gastroenterol Rep (2004) 0.76
Analysis of soluble angiogenic factors in Crohn's disease: a preliminary study. Gastroenterol Hepatol (2007) 0.76
Gut microbes in Crohn's disease: getting to know you better? Am J Gastroenterol (2008) 0.76
Defining subtypes of Crohn's disease patients: the ground work for translational research in inflammatory bowel disease. J Clin Gastroenterol (2003) 0.75
Combination therapy with infliximab and immunomodulators: is the glass half empty? Gastroenterology (2008) 0.75
Use of Cancer Stem Cells to Investigate the Pathogenesis of Colitis-associated Cancer. Inflamm Bowel Dis (2016) 0.75
Is genetic testing in IBD ready for prime time? Am J Gastroenterol (2004) 0.75
Serum Amyloid A as a Surrogate Marker for Mucosal and Histologic Inflammation in Patients with Crohn's Disease. Inflamm Bowel Dis (2016) 0.75
Mesalamine (5-aminosalicylic acid) therapy well tolerated in a patient with aspirin hypersensitivity and ulcerative colitis. J Clin Gastroenterol (2011) 0.75